ASCO 2019: Breakfast Brief – Genitourinary cancers
PD Dr. Richard Cathomas, Kantonsspital Chur, Graubünden, talks about the most interesting studies in genitourinary cancers presented at this year’s ASCO.
Video Contents00:00 Keynote-426: consistent benefit shown for the update, especially for patients with IMDC intermediate or poor risk and in pts whose tumors had sarcomatoid features 01:52 Carmena confirms last year's findings that CN is not superior to sunitinib alone in ITT population, but might be beneficial for patients with only one IMDC risk factor 02:47 Alliance: Addition of bevacizumab shows no benefit for patients with metastatic urothelial carcinoma 03:36 Pembrolizumab as maintenance therapy may improve responses achieved with first line chemotherapy in patients with metastatic urothelial cancer 05:45 Late breaking abstract shows most promising results for enfortumab vedotin monotherapy in pretreated patients
More from this topic:
ASCO 2019: Durable responses in patients with melanoma brain metastases with nivolumab/ipilimumab
11. 06. 2019
ASCO 2019: Pembrolizumab facilitates previously unmet 5-year-overall survival for NSCLC
06. 06. 2019